Executive summary 50 years after a noble but flawed attempt to eradicate malaria in the mid-
20th century, the global malaria community is once again seriously considering eradication …

Understanding and controlling the spread of antimalarial resistance, particularly to
artemisinin and its partner drugs, is a top priority. Plasmodium falciparum parasites resistant …

Background Partial artemisinin resistance is suspected if delayed parasite clearance (ie,
persistence of parasitaemia on day 3 after treatment initiation) is observed. Validated …

Artemisinin partial resistance may facilitate selection of Plasmodium falciparum resistant to
combination therapy partner drugs. We evaluated 99 P. falciparum isolates collected in 2021 …

Almost 20 years have passed since the first reference genome assemblies were published
for Plasmodium falciparum, the deadliest malaria parasite, and Anopheles gambiae, the …

Malaria, mostly due to Plasmodium falciparum infection in Africa, remains one of the most
important infectious diseases in the world. Standard treatment for uncomplicated P …

The last two decades have seen a surge in antimalarial drug development with product
development partnerships taking a leading role. Resistance of Plasmodium falciparum to the …

For more than five decades, Southeast Asia (SEA) has been fertile ground for the
emergence of drug-resistant Plasmodium falciparum malaria. After generating parasites …

Achieving a malaria-free world presents exciting scientific challenges as well as
overwhelming health, equity, and economic benefits. WHO and countries are setting …

Antimalarial drug resistance has historically arisen through convergent de novo mutations in
Plasmodium falciparum parasite populations in Southeast Asia and South America. For the …